Format

Send to

Choose Destination
See comment in PubMed Commons below
Cell Tissue Res. 2004 Oct;318(1):261-73. Epub 2004 Aug 11.

Stem cell therapy for Parkinson's disease: where do we stand?

Author information

1
Section for Neuronal Survival, Wallenberg Neuroscience Center, Lund University, BMC A10, 22184 Lund, Sweden. laurent.roybon@mphy.lu.se

Abstract

A major neuropathological feature of Parkinson's disease (PD) is the loss of nigrostriatal dopaminergic neuron. Patients exhibit motor symptoms, including bradykinesia, rigidity, and tremor. Neural grafting has been reported to restore striatial dopaminergic neurotransmission and induce symptomatic relief. The major limitation of cell replacement therapy for PD is the shortage of suitable donor tissue. The present review describes the possible sources of cells, including embryonic stem cells and somatic adult stem cells, both of which potentially could be used in cell therapy for PD, and discusses the advantages and disadvantages of each cell type.

PMID:
15309619
DOI:
10.1007/s00441-004-0946-y
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center